CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,072,693 | -19.1% | 1,587,854 | 0.0% | 5.57% | -18.2% |
| Q2 2023 | $89,142,124 | +24.1% | 1,587,854 | 0.0% | 6.80% | +37.1% |
| Q1 2023 | $71,818,636 | +11.3% | 1,587,854 | 0.0% | 4.96% | +36.9% |
| Q4 2022 | $64,546,265 | -37.9% | 1,587,854 | -0.1% | 3.63% | -30.1% |
| Q3 2022 | $103,907,000 | +7.5% | 1,590,002 | 0.0% | 5.19% | +4.5% |
| Q2 2022 | $96,624,000 | -73.6% | 1,590,002 | 0.0% | 4.96% | -53.0% |
| Q1 2022 | $365,593,000 | +203.4% | 1,590,002 | 0.0% | 10.56% | +333.7% |
| Q4 2021 | $120,490,000 | -32.3% | 1,590,002 | 0.0% | 2.44% | +15.2% |
| Q3 2021 | $177,969,000 | -30.9% | 1,590,002 | 0.0% | 2.11% | -37.0% |
| Q2 2021 | $257,405,000 | +32.9% | 1,590,002 | 0.0% | 3.35% | -22.9% |
| Q1 2021 | $193,742,000 | -20.4% | 1,590,002 | 0.0% | 4.35% | -32.3% |
| Q4 2020 | $243,445,000 | +83.1% | 1,590,002 | 0.0% | 6.43% | +14.2% |
| Q3 2020 | $132,988,000 | -13.4% | 1,590,002 | -23.9% | 5.63% | -8.8% |
| Q2 2020 | $153,644,000 | +73.3% | 2,090,678 | 0.0% | 6.18% | +33.3% |
| Q1 2020 | $88,666,000 | -30.4% | 2,090,678 | 0.0% | 4.63% | -23.1% |
| Q4 2019 | $127,322,000 | +48.6% | 2,090,678 | 0.0% | 6.02% | -15.1% |
| Q3 2019 | $85,697,000 | -13.0% | 2,090,678 | 0.0% | 7.10% | +2.9% |
| Q2 2019 | $98,471,000 | +31.9% | 2,090,678 | 0.0% | 6.90% | +77.9% |
| Q1 2019 | $74,679,000 | +25.0% | 2,090,678 | 0.0% | 3.88% | +63.7% |
| Q4 2018 | $59,731,000 | -35.6% | 2,090,678 | 0.0% | 2.37% | -40.8% |
| Q3 2018 | $92,722,000 | -24.5% | 2,090,678 | 0.0% | 4.00% | -30.5% |
| Q2 2018 | $122,848,000 | -22.9% | 2,090,678 | -40.0% | 5.76% | -18.8% |
| Q1 2018 | $159,275,000 | +110.6% | 3,484,464 | +8.2% | 7.08% | +126.1% |
| Q4 2017 | $75,623,000 | +31.4% | 3,220,728 | 0.0% | 3.13% | +55.4% |
| Q3 2017 | $57,554,000 | +11.5% | 3,220,728 | 0.0% | 2.02% | +7.4% |
| Q2 2017 | $51,596,000 | -26.4% | 3,220,728 | 0.0% | 1.88% | -23.0% |
| Q1 2017 | $70,115,000 | +7.5% | 3,220,728 | 0.0% | 2.44% | -6.0% |
| Q4 2016 | $65,252,000 | – | 3,220,728 | – | 2.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |